52 related articles for article (PubMed ID: 9388510)
1. [Evaluation of antitumor effect of chemotherapy for pancreatic cancer].
Okada S
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2031-5. PubMed ID: 9388510
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of therapeutic effect of chemotherapy with reference to clinical benefit response].
Okada S
Gan To Kagaku Ryoho; 2000 May; 27(5):696-701. PubMed ID: 10832437
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Yamao T; Kai S; Kazami A; Koizumi K; Handa T; Takemoto N; Maruyama M
Jpn J Clin Oncol; 1999 Nov; 29(11):550-5. PubMed ID: 10678558
[TBL] [Abstract][Full Text] [Related]
4. Value of serial carcinoembryonic antigen levels in evaluating the response to chemotherapy in patients with advanced digestive cancers.
Ychou M; Duffour J; Kramar A; Grenier J
Oncol Rep; 1998; 5(5):1245-50. PubMed ID: 9683844
[TBL] [Abstract][Full Text] [Related]
5. Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin.
Kikuchi H; Ujiie S; Kanamaru R
Intern Med; 1998 Jul; 37(7):635-7. PubMed ID: 9711896
[TBL] [Abstract][Full Text] [Related]
6. The French experience with infusional 5-FU in gastric and pancreatic cancer.
Ducreux M; Rougier P
J Infus Chemother; 1996; 6(4):203-5. PubMed ID: 9229316
[TBL] [Abstract][Full Text] [Related]
7. Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer.
Klapdor R; Bahlo M; Babinsky A; Brenzinger ML
Anticancer Res; 2007; 27(4A):1789-94. PubMed ID: 17649774
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer.
Okusaka T; Okada S; Ishii H; Nose H; Nakasuka H; Nakayama H; Nagahama H
Jpn J Clin Oncol; 1996 Aug; 26(4):215-20. PubMed ID: 8765178
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of unresectable pancreatic cancer responding to combined chemotherapy with cisplatin, PSK and UFT].
Sohma M; Kitagawa T; Okano S; Utsumi M; Mutoh E; Takeda S; Kanda M; Suzuki Y; Okamura K; Namiki M
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1926-9. PubMed ID: 3109332
[TBL] [Abstract][Full Text] [Related]
11. [Changes in tumor markers CEA, Ca 19-9 and Ca 125 in monitoring of response to chemotherapy in elderly patients with advanced gastric cancer].
Caponetti R; Caponetti T; Vici P
Clin Ter; 2002; 153(6):373-5. PubMed ID: 12645392
[TBL] [Abstract][Full Text] [Related]
12. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
Klapdor R; Bahlo M; Babinsky A
Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
[TBL] [Abstract][Full Text] [Related]
13. Tumor marker CEA in monitoring of response to tegafur-uracil and folinic acid in patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(44):388-92. PubMed ID: 11995458
[TBL] [Abstract][Full Text] [Related]
14. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
15. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
16. A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy.
Kosakamoto H; Okada S; Ueno H; Okusaka T; Ikeda M; Tanaka N; Yoshimori M; Matsuno Y
Hepatogastroenterology; 1999; 46(28):2621-4. PubMed ID: 10522052
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
18. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
Park YA; Sohn SK; Seong J; Baik SH; Lee KY; Kim NK; Cho CW
J Surg Oncol; 2006 Feb; 93(2):145-50. PubMed ID: 16425302
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials.
Ishii H; Furuse J; Nakachi K; Suzuki E; Yoshino M
Jpn J Clin Oncol; 2005 Oct; 35(10):601-6. PubMed ID: 16172174
[TBL] [Abstract][Full Text] [Related]
20. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
Ishii H; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1997; 44(13):279-83. PubMed ID: 9058159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
